메뉴 건너뛰기




Volumn 18, Issue 7, 2012, Pages 1821-1823

The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN GP 100; HLA A ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; MONTANIDE ISA 51;

EID: 84859414476     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0409     Document Type: Article
Times cited : (26)

References (12)
  • 1
    • 84859393995 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma
    • Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47.
    • (2012) Clin Cancer Res , vol.18 , pp. 2039-2047
    • Prieto, P.A.1    Yang, J.C.2    Sherry, R.M.3    Hughes, M.S.4    Kammula, U.S.5    White, D.E.6
  • 4
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    Weber, J.5    Garbe, C.6
  • 9
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
    • (2009) Clin Cancer Res , vol.15 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3    Weber, J.S.4    Hamid, O.5    Lebbe, C.6
  • 10
    • 77950258677 scopus 로고    scopus 로고
    • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival
    • Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-75.
    • (2010) Cancer , vol.116 , pp. 1767-1775
    • Ku, G.Y.1    Yuan, J.2    Page, D.B.3    Schroeder, S.E.4    Panageas, K.S.5    Carvajal, R.D.6
  • 11
    • 78650439466 scopus 로고    scopus 로고
    • Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials
    • Wolchok JD, Weber JS, Hamid O, Lebbe C, Maio M, Schadendorf D, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9.
    • (2010) Cancer Immun , vol.10 , pp. 9
    • Wolchok, J.D.1    Weber, J.S.2    Hamid, O.3    Lebbe, C.4    Maio, M.5    Schadendorf, D.6
  • 12
    • 79960299888 scopus 로고    scopus 로고
    • Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    • Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
    • (2011) Clin Cancer Res , vol.17 , pp. 4550-4557
    • Rosenberg, S.A.1    Yang, J.C.2    Sherry, R.M.3    Kammula, U.S.4    Hughes, M.S.5    Phan, G.Q.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.